Evidence map›Paper›PMID 39406720›Full record

ArticleScientific reports2024

Ongoing transmission of trachoma in low prevalence districts in Mozambique: results from four cross-sectional enhanced impact surveys, 2022.

Henis Mior Sitoe, William E Oswald, Felizmina Zita, Mawo Fall, Tamimo Momade, Molly W Adams, Rebecca M Flueckiger, Scott McPherson, Sabrina Eyob, Thuy Doan and 13 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Henis Mior Sitoe *Ministério da Saúde, Maputo, Mozambique.
William E Oswald *RTI International, Research Triangle Park, USA. woswald@rti.org.
Felizmina ZitaMinistério da Saúde, Maputo, Mozambique.
Mawo FallRTI International, Maputo, Mozambique.
Tamimo MomadeRTI International, Maputo, Mozambique.
Molly W AdamsRTI International, Research Triangle Park, USA.
Rebecca M FlueckigerRTI International, Research Triangle Park, USA.
Scott McPhersonRTI International, Research Triangle Park, USA.
Sabrina EyobRTI International, Research Triangle Park, USA.
Thuy DoanF.I. Proctor Foundation and University of California San Francisco, San Francisco, USA.
Thomas M LietmanF.I. Proctor Foundation and University of California San Francisco, San Francisco, USA.
Benjamin F ArnoldF.I. Proctor Foundation and University of California San Francisco, San Francisco, USA.
Karana WickensOak Ridge Institute for Science and Education, Oak Ridge, USA.
Sarah GwynCenters for Disease Control and Prevention, Atlanta, USA.
Diana L MartinCenters for Disease Control and Prevention, Atlanta, USA.
Mabula KasubiMuhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Sarah BoydInternational Trachoma Initiative, Task Force for Global Health, Decatur, USA.
Ana BakhtiariInternational Trachoma Initiative, Task Force for Global Health, Decatur, USA.
Cristina JimenezSightsavers, Haywards Heath, UK.
Anthony W SolomonGlobal Neglected Tropical Diseases Programme, World Health Organization, Geneva, Switzerland.
Emma M Harding-EschLondon School of Hygiene & Tropical Medicine, London, UK.
Upendo J MwingiraRTI International, Research Triangle Park, USA.
Jeremiah M NgondiRTI International, Research Triangle Park, USA.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Mozambique is making progress towards elimination of trachoma as a public health problem, but in some districts trachomatous inflammation-follicular (TF) prevalence remains above the 5% elimination threshold despite years of various interventions, including antibiotic mass drug administration. To characterize transmission in four districts, we incorporated testing of ocular infection and serology into routine trachoma impact surveys (TIS) in August 2022. We examined residents aged ≥ 1 year for trachoma and collected information on household water, sanitation, and hygiene. Among children aged 1-9 years, we tested conjunctival swabs for Chlamydia trachomatis nucleic acid and dried blood spots for C. trachomatis antibodies. We modeled age-dependent seroprevalence to estimate seroconversion rate (SCR). We examined 4841 children aged 1-9 years. TF prevalence ranged between 1.1 and 6.0% with three districts below the 5% threshold. PCR-confirmed infection prevalence ranged between 1.1 and 4.8%, and Pgp3 seroprevalence ranged between 8.8 and 24.3%. Pgp3 SCR was 1.9 per 100 children per year in the district with the lowest TF prevalence. Two other districts with TF < 5% had SCR of 5.0 and 4.7. The district with TF ≥ 5% had a SCR of 6.0. This enhanced TIS furthered understanding of transmission in these districts and provides information on additional indicators for monitoring trachoma programs.

Indexed as

Chlamydia trachomatisTrachomaAntibodies, BacterialChildChild, PreschoolCross-Sectional StudiesFemaleHumansInfantMaleMozambiquePrevalenceSeroepidemiologic StudiesAntibodies, Bacterial

Identifiers

PMID39406720
PMCPMC11480103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.